Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns.
Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 percent to close at $3.80 as investors began repositioning portfolios ahead of key business updates next week.
In a notice to investors, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) said that it is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, where investors are expected to watch for updates about its pipeline.
Employees on the job at Recursion Pharmaceuticals’ headquarters. Photo from Recursion Pharmaceuticals
One of its pipelines under clinical trial is the REC-4881, an orally available inhibitor to treat familial adenomatous polyposis—a genetically defined disease driven by APC loss.
According to Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), it has initiated an engagement with the Food and Drug Administration to align on a potential registrational study design, with an update expected in the second half of 2026.
In other news, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) posted an improvement in its earnings performance in the first quarter of the year, having slashed its net loss by 42 percent to $117.5 million from $202.5 million in the same period last year.
Total revenues, which come solely from collaboration agreements, fell by 56 percent to $6.47 million from $14.7 million year-on-year due to lower revenues from Roche following the completion of certain project phases in the period earlier.
While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
